Table 2.

Summary of active clinical trials evaluating dipyridamole use in cardiovascular disease

NCT number	Trial name	Phase	Year	Summary
NCT04424901	Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19	Phase 2	2020	Evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized patients
NCT04391179	Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19	Phase 2	2020	Evaluate whether 14 days of treatment with dipyridamole will reduce excessive blood clotting in COVID-19
NCT04666454	BROKEN-SWEDEHEART-Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome	Phase 2	2020	Adenosine + dipyridamole vs. apixaban vs. ESC standard of care vs. placebo for treating takotsubo syndrome